Deoxyribonucleic Acid (DNA) Repair Alkylating Agent Market Report 2025

The deoxyribonucleic acid (DNA) repair alkylating agent market size has grown strongly in recent years. It will grow from $3.41 billion in 2024 to $3.7 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising number of hospitals and specialized cancer treatment clinics, increased regulatory approvals of various alkylating agents, expanded healthcare access in developing regions, enhanced cancer awareness initiatives by governments and NGOs, and the broader adoption of chemotherapy treatments.

The deoxyribonucleic acid (DNA) repair alkylating agent market size is expected to see strong growth in the next few years. It will grow to $5.05 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The projected growth in the forecast period can be attributed to the rising adoption of personalized medicine and DNA repair-targeted therapies, an expanding pipeline of clinical trials, increased focus on geriatric oncology, the growth of companion diagnostics for chemotherapy, and enhanced government funding for rare cancers. Key trends anticipated during this period include a move toward targeted DNA repair inhibitors, the development of dual-action chemotherapy agents, the integration of AI in the discovery of alkylating drugs, growth in biosimilars of established alkylating agents, and the use of biomarkers to improve treatment selection.

The increasing prevalence of cancer cases worldwide is expected to drive the growth of the DNA repair alkylating agent market moving forward. Cancer is a disease in which certain cells in the body begin to grow uncontrollably and may spread to nearby tissues or other parts of the body. The global rise in cancer cases is largely due to aging populations, who face a higher risk of developing cancer. DNA repair alkylating agents treat cancer by damaging the DNA of rapidly dividing tumor cells, thereby preventing their multiplication. This damage results in cell death or growth inhibition, helping to control tumor progression. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately 20 million new cancer cases were diagnosed in 2022, with 9.7 million deaths worldwide. Additionally, an estimated 53.5 million people were alive within five years after a cancer diagnosis. Therefore, the global increase in cancer prevalence is fueling growth in the DNA repair alkylating agent market.

Key companies in the DNA repair alkylating agent market are focusing on developing advanced therapies such as nitrogen mustard-based drugs to improve treatment effectiveness and broaden the range of cancers treated while enhancing safety profiles. Nitrogen mustard drugs are alkylating agents that kill cancer cells by cross-linking their DNA, thus blocking replication. These drugs are commonly used in chemotherapy for cancers like leukemia and lymphoma. For instance, in November 2022, Alembic Pharmaceuticals, an India-based pharmaceutical firm, received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for cyclophosphamide capsules, available in 25 mg and 50 mg strengths. This alkylating agent is indicated for treating various malignancies as well as minimal change nephrotic syndrome in pediatric patients.

In June 2024, Dr. Reddy’s Laboratories USA, a US-based pharmaceutical manufacturer involved in producing drugs including anticancer alkylating agents, partnered with Ingenus Pharmaceuticals LLC to expand access to quality cancer treatments. This collaboration aims to increase the availability of cyclophosphamide injection in the U.S. market by combining Ingenus’s manufacturing capabilities with Dr. Reddy’s strong distribution network. Ingenus Pharmaceuticals LLC is a US-based producer of affordable generic medications offering cost-effective solutions for patients.

Major players in the deoxyribonucleic acid (dna) repair alkylating agent market are Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Limited, Baxter International, Fresenius Kabi, Intas Pharmaceuticals, Dr. Reddy’s Laboratories, Aurobindo Pharma, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Alembic Pharmaceuticals Limited, Natco Pharma Ltd, Medac GmbH, Celon Laboratories, Azurity Pharmaceuticals, Meitheal Pharmaceuticals Inc, Acrotech Biopharma, Navinta LLC, STI Pharma LLC, Emcure Pharmaceuticals, Halsted Pharma Pvt. Ltd., MSN Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals Co. Ltd.

North America was the largest region in the deoxyribonucleic acid (DNA) repair alkylating agent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in deoxyribonucleic acid (DNA) repair alkylating agent report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the deoxyribonucleic acid (DNA) repair alkylating agent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The deoxyribonucleic acid (DNA) repair alkylating agent market consists of sales of ethylenimines and methylmelamines, hydrazines, aziridines, and procarbazine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The deoxyribonucleic acid (DNA) repair alkylating agents market research report is one of a series of new reports that provides deoxyribonucleic acid (DNA) repair alkylating agents market statistics, including the deoxyribonucleic acid (DNA) repair alkylating agents industry global market size, regional shares, competitors with the deoxyribonucleic acid (DNA) repair alkylating agents market share, detailed deoxyribonucleic acid (DNA) repair alkylating agents market segments, market trends, opportunities, and any further data you may need to thrive in the deoxyribonucleic acid (DNA) repair alkylating agents industry. This deoxyribonucleic acid (DNA) repair alkylating agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

A deoxyribonucleic acid (DNA) repair alkylating agent is a chemotherapy drug that attaches alkyl groups to DNA molecules, causing damage that disrupts the cancer cell’s ability to replicate and survive. These agents create covalent bonds with DNA, resulting in cross-linking or mispairing of DNA bases, which can lead to cell cycle arrest or apoptosis if the damage remains unrepaired.

The main categories of DNA repair alkylating agents include nitrogen mustards, nitrosoureas, alkyl sulfonates, triazines, and others. Nitrogen mustards are powerful bifunctional alkylating agents widely used in cancer treatment, though they are also associated with side effects such as skin damage, inflammation, and potential carcinogenic risks. These agents have applications in cancer therapy, research and development, and other fields, and are utilized by end users like hospitals, research institutions, pharmaceutical companies, and more.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.